



Response document for MHRA public consultation on the  
proposal to make Dovonex Psoriasis Ointment available in Pharmacies

ANNEX 1

Ref: ARM95

Your details

Name:

[REDACTED]

Position (if applicable):

Dermatology Pharmacist

Organisation (if applicable):

Barts Health NHS Trust

Email:

1. Do you consider that Dovonex Psoriasis Ointment should be available as a Pharmacy medicine?

Yes

No

Not sure

Please provide any comments or evidence to support your response:

It's a safe medicine which could help successfully control mild or moderate plaque psoriasis. It should be accessible to psoriasis patient without visiting GP; this kind of topical treatment could be used under pharmacist supervision. Calcipotriol ointment has been monitored by doctors long enough and has its place settled in the psoriasis treatment. Risk of adverse reactions is very low and could be easily controlled.

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Dovonex Psoriasis Ointment?

Leaflet should say that Dovonex is only for adults use.

3. Do you have any other comments on the reclassification?

What is going to happen to Dovonex cream, which is tolerated better by patients?

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes

Partially\*

No

\*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email ([reclassification@mhra.gsi.gov.uk](mailto:reclassification@mhra.gsi.gov.uk)) to arrive by **20 April 2017**. Contributions received after that date cannot be included in the exercise.